TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35761370
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 800 mg stat then 400 mg weekly
Study: 33812327
Drug: NSAID +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID + magnesium (400 mg etodolac twice a day with 365 mg oral magnesium supplementation)
Study: 33812327
Drug: NSAID alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID alone (400 mg etodolac twice a day)
Study: 33812327
Drug: NSAID +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID + paracetamol (400 mg etodolac twice a day with 500 mg paracetamol twice a day)
Study: 32179149
Drug: CMS loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMS loading dose (LD group) of 4 mg CBA/kg/dose
Study: 32179149
Drug: Standard initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard initial dose (NLD group) of 2.5 mg (12-h interval) or 1.7 mg (8-h interval) of CBA/kg/dose
Study: 32868437
Drug: Serological measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serological measures of transmission based on antibody response to S. mansoni soluble egg antigen (SEA)
Study: 33506411
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with 5 mg/kg of Se from SeGlu
Study: 33506411
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with 0.3 mg/kg of Se from sodium selenite (SS)
Study: 32514756
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day of elemental zinc for three months
Study: 34154634
Drug: Supervised training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised training of activities of daily living (ADL), resistance, and stability, twice a week for 1 hour per session
Study: 34154634
Drug: Daily home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home-based exercise representing regular outpatient care
Study: 34028460
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate + rhinophototherapy
Study: 32948120
Drug: Singing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singing group intervention (34 bi-weekly sessions, 2 hours each for 4 months)
Study: 36722208
Drug: Combination exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination exercise
Study: 36182594
Drug: EZ10/AS10 (ezetimibe/atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZ10/AS10 (ezetimibe/atorvastatin 10/10 mg FDC)
Study: 36182594
Drug: EZ10/AS20 (ezetimibe/atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZ10/AS20 (ezetimibe/atorvastatin 10/20 mg FDC)
Study: 36182594
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg (AS20)
Study: 36182594
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg (AS40)
Study: 32645934
Drug: WHEY-ALL (whey
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHEY-ALL (whey protein, 3.1 µg B12/day)
Study: 32645934
Drug: COLL (collagen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: COLL (collagen, 1.3 µg B12/day)
Study: 32645934
Drug: CARB (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARB (maltodextrin, 0.3 µg B12/day)
Study: 34426397
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (0.1 mg/kg)
Study: 32810504
Drug: Inhaled diesel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled diesel exhaust (DE) at 200 μg/m3
Study: 32810504
Drug: Antioxidant pretreatment
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant pretreatment (1000 mg ascorbate for 7 days and 1200 mg N-acetylcysteine 1 day prior to exposure)
Study: 36475905
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (3 doses of 2.7 × 10^6 PfSPZ)
Study: 32141817
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg cholecalciferol
Study: 32182747
Drug: DHA +
Normalized name: PNV-DHA + Docusate Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA + EPA supplementation (2.1 g/day of DHA + 240 mg/day of EPA)
Study: 32301973
Drug: Autologous ADASC
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous ADASC implantation (G-1)
Study: 32301973
Drug: Decellularized human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decellularized human corneal stroma (G-2)
Study: 32301973
Drug: Autologous ADASCs
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous ADASCs + decellularized human corneal stroma (G-3)
Study: 35045722
Drug: DPP4 inhibition
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP4 inhibition (sitagliptin) during ramipril treatment
Study: 35045722
Drug: Aprepitant (NK1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (NK1 receptor blocker) during ramipril or valsartan treatment
Study: 35045722
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during ramipril treatment
Study: 35045722
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during valsartan treatment
Study: 35045722
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during amlodipine treatment
Study: 35045722
Drug: Sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin + placebo during ramipril treatment
Study: 35045722
Drug: Sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin + placebo during valsartan treatment
Study: 35045722
Drug: Sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin + placebo during amlodipine treatment
Study: 35045722
Drug: Sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin + aprepitant during ramipril treatment
Study: 35045722
Drug: Sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin + aprepitant during valsartan treatment
Study: 35045722
Drug: Sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin + aprepitant during amlodipine treatment
Study: 37286319
Drug: Treatment-as-usual (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (standard care).
Study: 32496104
Drug: Group-administered stress
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-administered stress management with a trauma focus (SMT)
Study: 32496104
Drug: Group-administered psychological
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-administered psychological first aid (PFA)
Study: 34437779
Drug: Sham Treatment
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Treatment
Study: 32307650
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (EG) - intrabronchially inoculated with M. haemolytica (6.5×10^6 CFU/mL)
Study: 35522618
Drug: Leap motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leap motion control and conventional therapy
Study: 33095139
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg ianalumab
Study: 33095139
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg ianalumab
Study: 36342163
Drug: Olpasiran 10
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 10 mg every 12 weeks
Study: 36342163
Drug: Olpasiran 75
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 75 mg every 12 weeks
Study: 36342163
Drug: Olpasiran 225
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 225 mg every 12 weeks
Study: 36342163
Drug: Olpasiran 225
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 225 mg every 24 weeks
Study: 33529342
Drug: CT (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (control group with sterile saline solution)
Study: 33529342
Drug: ST (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST (saline solution containing Salmonella Typhimurium)
Study: 32819400
Drug: Adjunct treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct treatment
Study: 34518033
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with choline fenofibrate and statin
Study: 33125266
Drug: IGF-1 (insulin-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-1 (insulin-like growth factor 1)
Study: 32682938
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone acetonide + 2% lidocaine hydrochloride
Study: 32682938
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg triamcinolone acetonide + 2% lidocaine hydrochloride
Study: 32682938
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (40 mg and 10 mg)
Study: 35894410
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution (100 ml)
Study: 35894410
Drug: Carbohydrate popsicle
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate popsicle (100 ml)
Study: 33247691
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation of 6,000 IU (1.8 mg RAEs) per day
Study: 33535899
Drug: Whole-Body Vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-Body Vibration (WBV) therapy, Compex-Winplate™, 3 sessions of 15 minutes per week for 8 weeks
Study: 36433713
Drug: danuglipron 40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: danuglipron 40-120 mg BID
Study: 33741815
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb therapies after stroke
Study: 35398192
Drug: Supportive resource
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive resource activation treatment (STARK)
Study: 33458928
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract nutraceutical (PE), 320 mg phenolics/day for 1 month
Study: 33185527
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol (0.5%) cream, applied three times daily for three months
Study: 34341578
Drug: Toripalimab plus
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab plus GP chemotherapy
Study: 34341578
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus GP chemotherapy
Study: 32204978
Drug: Curcumin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin group (receiving 100 mL of orange juice with 12 g of carrot and 2.5 g of turmeric after each dialysis session/week for 3 months)
Study: 32083522
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of MSM for 16 weeks
Study: 32083522
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day of MSM for 16 weeks
Study: 32819439
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus albumin (20 g in 100 mL) every 12 h for 4 days
Study: 35223910
Drug: Spinal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal morphine (SM) 0.1 mg
Study: 35223910
Drug: Bilateral landmark‐oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral landmark‐oriented TAP block with 20 ml of 0.25% bupivacaine
Study: 34711232
Drug: umeclidinium/vilanterol 62.5/25
Normalized name: umeclidinium/vilanterol 62.5/25 MCG/INHAL Dry Powder Inhaler, 7 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: umeclidinium/vilanterol 62.5/25 µg once daily
Study: 34711232
Drug: umeclidinium 62.5
Normalized name: UMECLIDINIUM 62.5MCG 7D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: umeclidinium 62.5 µg once daily
Study: 34711232
Drug: salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol 50 µg twice daily
Study: 33704597
Drug: Early angiography
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early angiography and revascularization with guideline‐directed medical therapy
Study: 32789516
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg D-Cycloserine (DCS)
Study: 32789516
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg D-Cycloserine (DCS)
Study: 33783470
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral atomoxetine
Study: 34487919
Drug: Carrageenan-containing gel
Normalized name: Carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrageenan-containing gel
Study: 34155082
Drug: Oral fat‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat‐based energy‐dense supplement (300 kcal daily) for 12 weeks
Study: 36123011
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg once daily for 24 months
Study: 616388350
Drug: Amlodipine/atorvastatin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/atorvastatin (Group 3)
Study: 35263421
Drug: Levonorgestrel Implant
Normalized name: levonorgestrel IMPLANT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel Implant (LNG-implant)
Study: 34111874
Drug: Diagnosis-specific cognitive
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis-specific cognitive behavioral therapy (dCBT)
Study: 32064971
Drug: Extended-cycle regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-cycle regimen of combined oral contraceptive (ethinylestradiol 30μg and levonorgestrel 150μg)
Study: 37142540
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL (IGlar‐100)
Study: 35441666
Drug: Befriending therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befriending therapy
Study: 37415001
Drug: Midazolam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (7.5 mg orally)
Study: 32652528
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg every 2 weeks (q2w)
Study: 32652528
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg every 4 weeks (q4w)
Study: 32184313
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (Circadin) 2 mg at night for 6 weeks
Study: 33118052
Drug: Ayahuasca (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (single dose)
Study: 32901672
Drug: Oral aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral aprepitant (80 mg), intravenous dexamethasone (8 mg), and palonosetron (0.075 mg)
Study: 32901672
Drug: Oral placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo, intravenous dexamethasone (4 mg), and palonosetron (0.075 mg)
Study: 35025993
Drug: Olezarsen 10
Normalized name: olezarsen 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen 10 mg every 4 weeks
Study: 35025993
Drug: Olezarsen 15
Normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen 15 mg every 2 weeks
Study: 35025993
Drug: Olezarsen 10
Normalized name: olezarsen 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen 10 mg every week
Study: 35025993
Drug: Olezarsen 50
Normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen 50 mg every 4 weeks
Study: 34371824
Drug: Crocodile blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocodile blood supplementation (CB) - 1 g day−1 for 18 days
Study: 34180141
Drug: Combined Metabolic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Metabolic Activators (CMAs) including l-serine, N-acetyl-l-cysteine, nicotinamide riboside, and l-carnitine tartrate
Study: 33096365
Drug: Take-home naloxone
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take-home naloxone (THN) kits, including two doses of naloxone
Study: 35811182
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus home exercise program (ST+HEP)
Study: 32195861
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group (cephalexin 500 mg every 6 hours for 7 days)
Study: 32195861
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (identical capsules)
Study: 34309926
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) algorithm for automatic classification of fetal occiput position using transperineal ultrasound (TPU) images.
Study: 34689142
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser + AmF/NaF/SnCl2 solution
Study: 34689142
Drug: AmF/NaF/SnCl2 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF/NaF/SnCl2 solution
Study: 34493253
Drug: Imagery Rescripting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery Rescripting (ImRs) therapy
Study: 34493253
Drug: 3-month SUD
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month SUD treatment only
Study: 34493253
Drug: Simultaneous SUD/PTSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous SUD/PTSD treatment
Study: 34493253
Drug: Sequential SUD/PTSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential SUD/PTSD treatment
Study: 32553435
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock-wave therapy (rESWT)
Study: 32553435
Drug: Ultrasound-guided low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultrasound-guided low-dose intra-articular steroid injection (20 mg of triamcinolone acetonide)
Study: 34543477
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks (35 cycles)
Study: 32609980
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg every 12 hours for 4 to <10 kg, 1000 mg every 12 hours for 10 to <14 kg, 1500 mg every 12 hours for 14 to <20 kg)
Study: 33864736
Drug: DS-Cav1 vaccine
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-Cav1 vaccine 50 μg with AlOH
Study: 33864736
Drug: DS-Cav1 vaccine
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-Cav1 vaccine 150 μg with AlOH
Study: 33864736
Drug: DS-Cav1 vaccine
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-Cav1 vaccine 500 μg with AlOH
Study: 33864736
Drug: DS-Cav1 vaccine
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-Cav1 vaccine (all doses)
Study: 34352922
Drug: Foley with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley with concurrent prostaglandin (Foley-PGE)
Study: 34352922
Drug: Foley with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley with concurrent oxytocin (Foley-oxytocin)
Study: 32629657
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonoperative treatment)
Study: 33480569
Drug: Intravenous iopamidol
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous iopamidol at a dose of 480 mg iodine (I)/kg, sampled at 5 min, 1 hr, 6 hr, 24 hr, and 48 hr postinjection.
Study: 35640175
Drug: Muramyl peptides
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muramyl peptides (200 micrograms administered intramuscularly daily for 7 days)
Study: 35938325
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with conventional western medicine therapy
Study: 35938325
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine therapy
Study: 39186921
Drug: Valbenazine 80
Normalized name: valbenazine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine 80 mg
Study: 39186921
Drug: Valbenazine 40
Normalized name: valbenazine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine 40 mg
Study: 32403906
Drug: Acidif plus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidif plus® (two tablets per day for 7 days)
Study: 35040415
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg OD or 200 mg BID
Study: 32539079
Drug: Hookworm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hookworm treatment (25 Necator americanus larvae transcutaneously)
Study: 33660875
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg daily for 4 weeks
Study: 32534626
Drug: Anti-SARS-CoV-2 IgG
Normalized name: Anti-SARS-CoV-2 IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-SARS-CoV-2 IgG antibodies testing
Study: 34076308
Drug: Calcitriol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (1 μg for 1 week before surgery)
Study: 35113137
Drug: Intravitreal pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravitreal pegcetacoplan monthly (15 mg)